Ripasudil is a pharmacological agent primarily used in the treatment of glaucoma and ocular hypertension. It functions as a Rho kinase inhibitor, which helps to lower intraocular pressure by enhancing the outflow of aqueous humor from the eye. The chemical structure of Ripasudil includes a piperazine moiety, contributing to its biological activity. It is typically administered as an eye drop solution, allowing for localized treatment with minimal systemic absorption. The substance has been shown to have a favorable safety profile, with common side effects including ocular hyperemia and discomfort. Ripasudil's mechanism of action involves the modulation of the cytoskeletal dynamics within trabecular meshwork cells, promoting increased drainage of intraocular fluid. This makes it a valuable option in managing conditions associated with elevated intraocular pressure, particularly in patients who may not respond adequately to other therapies. As with any medication, it is essential for patients to consult healthcare professionals for personalized advice and to understand potential interactions with other treatments.

Ripasudil

223645-67-8: Ripasudil, 1H-1,4-Diazepine, 1-[(4-fluoro-5-isoquinolinyl)sulfonyl]hexahydro-2-methyl-, (2S)-, 4-Fluoro-5-[[(2S)-hexahydro-2-methyl-1H-1,4-diazepin-1-yl]sulfonyl]isoquinoline, K 115, Isoquinoline, 4-fluoro-5-[[(2S)-hexahydro-2-methyl-1H-1,4-diazepin-1-yl]sulfonyl]-

Ripasudil free base (K-115 (free base)) is a selective and potent ROCK inhibitor, is a novel and potent antiglaucoma agent.

CAS 223645-67-8: Ripasudil

Ripasudil free base

Ref: TM-T7492

Ripasudil

Ref: 3D-FR145188

Ripasudil

Ref: 4Z-R-164001